Catherine M Bollard

List of Publications by Year
in descending order

307 papers	16,180 citations	16411 64 h-index	19690 117 g-index
315 all docs	315 docs citations	315 times ranked	13692 citing authors

#	Article	IF	Citations
1	EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target. Blood, 2022, 139, 983-994.	0.6	17
2	Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains. Cytotherapy, 2022, 24, 10-15.	0.3	6
3	Tumor-associated antigenâ€“specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. Blood Advances, 2022, 6, 473-485.	2.5	11
4	High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Advances, 2022, 6, 452-459.	2.5	11
5	Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort. Bone Marrow Transplantation, 2022, 57, 279-281.	1.3	2
6	Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients. Transplantation and Cellular Therapy, 2022, 28, 116.e1-116.e7.	0.6	11
7	Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. Blood Advances, 2022, 6, 2897-2907.	2.5	13
8	Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel. Pediatric Hematology and Oncology, 2022, , 1-9.	0.3	0
9	A biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation. Blood Advances, 2022, 6, 1866-1878.	2.5	4
10	The generation and application of antigen-specific TÂcell therapies for cancer and viral-associated disease. Molecular Therapy, 2022, 30, 2130-2152.	3.7	19
11	Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. Blood, 2022, 140, 208-221.	0.6	13
12	Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Advances, 2022, 6, 2520-2534.	2.5	19
13	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. Journal of Clinical Oncology, 2022, 40, 2106-2118.	0.8	45
14	Reply to R. Lakhotia et al. Journal of Clinical Oncology, 2022, , JCO2102912.	0.8	0
15	Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific TÂcell therapy products. Molecular Therapy - Methods and Clinical Development, 2022, 25, 439-447.	1.8	4
16	Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy. Cytotherapy, 2022, 24, 802-817.	0.3	2
17	IMMU-19. Outcomes of Pediatric Patients with High-Risk CNS Tumors Treated with Multi-tumor associated antigen specific T cell (TAA-T) therapy: the ReMIND trial. Neuro-Oncology, 2022, 24, i85-i86.	0.6	1
18	Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood, 2021, 137, 1777-1791.	0.6	25

#	Article	IF	Citations
19	NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations. Transplantation and Cellular Therapy, 2021, 27, 21-35.	0.6	16
20	Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. Transplantation and Cellular Therapy, 2021, 27, 183.e1-183.e7.	0.6	6
21	Frontiers in cancer immunotherapyâ€"a symposium report. Annals of the New York Academy of Sciences, 2021, 1489, 30-47.	1.8	39
22	Preventative and Preemptive Strategies for EBV Infection and PTLD After HSCT. , 2021, , 239-251.		0
23	Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay. Cytotherapy, 2021, 23, 65-76.	0.3	10
24	Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood, 2021, 137, 3595-3603.	0.6	40
25	Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies. Cytotherapy, 2021, 23, 694-703.	0.3	7
26	Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy. Expert Review of Clinical Immunology, 2021, 17, 643-659.	1.3	5
27	T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. Journal of Clinical Oncology, 2021, 39, 1415-1425.	0.8	30
28	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. Journal of Experimental Medicine, 2021, 218, .	4.2	9
29	Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. Journal of Clinical Immunology, 2021, 41, 1146-1153.	2.0	45
30	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Blood Advances, 2021, 5, 2890-2900.	2.5	3
31	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Annals of Hematology, 2021, 100, 2529-2539.	0.8	12
32	Introduction to a review series on gene therapy and gene editing for sickle cell disease and hemophilia. Blood, 2021, 138, 913-913.	0.6	0
33	Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Blood Advances, 2021, 5, 3309-3321.	2.5	26
34	Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2021, 39, 3716-3724.	0.8	18
35	Using Molecular Stratification for Smart Combination Therapies. Journal of Clinical Oncology, 2021, 39, 3527-3530.	0.8	2
36	Novel TCR-like CAR-T cells targeting an HLAâˆ—0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia. Molecular Therapy - Methods and Clinical Development, 2021, 23, 296-306.	1.8	12

#	Article	IF	Citations
37	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3487-3487.	0.6	1
38	Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors. Nature Communications, 2021, 12, 6689.	5.8	25
39	SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 793197.	2.2	14
40	Flow-based analysis of cell division identifies highly active populations within plasma products during mixed lymphocyte cultures. Blood Transfusion, 2021, 19, 456-466.	0.3	1
41	HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform. Molecular Therapy - Methods and Clinical Development, 2020, 16, 11-20.	1.8	16
42	Generation of Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy. Journal of Infectious Diseases, 2020, 221, 578-588.	1.9	15
43	Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV. Molecular Therapy - Methods and Clinical Development, 2020, 19, 78-88.	1.8	10
44	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. Cytotherapy, 2020, 22, 474-481.	0.3	29
45	Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Blood Advances, 2020, 4, 3252-3257.	2.5	5
46	Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. Cancers, 2020, 12, 3603.	1.7	6
47	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV,the, 2020, 7, e602-e610.	2.1	11
48	The effects of Î²1 and Î²1+2 adrenergic receptor blockade on the exercise-induced mobilization and ex vivo expansion of virus-specific T cells: implications for cellular therapy and the anti-viral immune effects of exercise. Cell Stress and Chaperones, 2020, 25, 993-1012.	1.2	5
49	SARS-CoV-2â€“specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood, 2020, 136, 2905-2917.	0.6	108
50	Introduction to a How I Treat series on hematologic complications in pregnancy. Blood, 2020, 136, 2093-2093.	0.6	0
51	T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1. Frontiers in Immunology, 2020, 11, 575977.	2.2	4
52	Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups. Blood, 2020, 135, 1428-1437.	0.6	15
53	Rituximab for High-Risk, Mature B-Cell Non-Hodgkinâ€™s Lymphoma in Children. New England Journal of Medicine, 2020, 382, 2207-2219.	13.9	157
54	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Childrenâ€™s Oncology Group AALL0434. Journal of Clinical Oncology, 2020, 38, 3062-3070.	0.8	42

#	Article	IF	Citations
55	Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. , 2020, 8, e000796.		7
56	Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2020, 10, 298.	1.8	8
57	Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma. Nanomaterials, 2020, 10, 161.	1.9	25
58	Virus-specific T-cell therapies for patients with primary immune deficiency. Blood, 2020, 135, 620-628.	0.6	45
59	Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open, 2020, 10, e034629.	0.8	26
60	Introduction to a review series on understanding and treating primary immunodeficiency. Blood, 2020, 135, 591-591.	0.6	0
61	BCL-2 antagonism sensitizes cytotoxic T cellâ€“resistant HIV reservoirs to elimination ex vivo. Journal of Clinical Investigation, 2020, 130, 2542-2559.	3.9	77
62	Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231. Blood, 2020, 136, 11-12.	0.6	10
63	Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children's Oncology Group Trial-AHOD1331. Blood, 2020, 136, 41-42.	0.6	1
64	Tumor Associated Antigen Specific T Cells Given in Combination with Nivolumab for the Treatment of Hodgkin Lymphoma. Blood, 2020, 136, 18-18.	0.6	1
65	Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Advances, 2020, 4, 5745-5754.	2.5	19
66	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 45-63.	12.5	178
67	Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. Journal of Clinical Oncology, 2019, 37, 2349-2359.	0.8	56
68	T-cell therapies for T-cell lymphoma. Cytotherapy, 2019, 21, 935-942.	0.3	10
69	Generation of Zika virusâ€“specific T cells from seropositive and virus-naÃ¯ve donors for potential use as an autologous or â€œoff-the-shelfâ€•immunotherapeutic. Cytotherapy, 2019, 21, 840-855.	0.3	10
70	Driving the CAR to the Bone Marrow Transplant Program. Current Hematologic Malignancy Reports, 2019, 14, 561-569.	1.2	10
71	Iatrogenic immunodeficiency-associated lymphoproliferative disorder in a child with B-cell acute lymphoblastic leukemia. Pediatric Hematology and Oncology, 2019, 36, 309-316.	0.3	4
72	ROR1 and ROR2â€”novel targets for neuroblastoma. Pediatric Hematology and Oncology, 2019, 36, 352-364.	0.3	13

#	Article	IF	Citations
73	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
74	Medulloblastoma rendered susceptible to NK-cell attack by TGFÎ² neutralization. Journal of Translational Medicine, 2019, 17, 321.	1.8	32
75	Tâ€cell receptor sequencing demonstrates persistence of virusâ€specific T cells after antiviral immunotherapy. British Journal of Haematology, 2019, 187, 206-218.	1.2	29
76	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	1.3	86
77	Engineering the TGFÎ² Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma. Clinical Cancer Research, 2019, 25, 4400-4412.	3.2	52
78	Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders. Frontiers in Immunology, 2019, 10, 621.	2.2	4
79	ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. European Journal of Cancer, 2019, 110, 74-85.	1.3	39
80	Designing Magnetically Responsive Biohybrids Composed of Cord Blood-Derived Natural Killer Cells and Iron Oxide Nanoparticles. Bioconjugate Chemistry, 2019, 30, 552-560.	1.8	24
81	Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Advances, 2019, 3, 2057-2068.	2.5	27
82	Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 809-818.	2.0	16
83	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
84	Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease. Pediatric Blood and Cancer, 2019, 66, e27601.	0.8	5
85	Systemic Î²-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells. Frontiers in Immunology, 2019, 10, 3082.	2.2	36
86	HIV-Specific T Cells Generated from Naive T Cells Suppress HIV InÂVitro and Recognize Wide Epitope Breadths. Molecular Therapy, 2018, 26, 1435-1446.	3.7	18
87	Reprint of: Virus-Specific T Cells: Broadening Applicability. Biology of Blood and Marrow Transplantation, 2018, 24, S1-S6.	2.0	7
88	Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study. Lancet Haematology,the, 2018, 5, e44-e52.	2.2	14
89	Human papilloma virusâ€“specific T cells can be generated from naÃ¯ve T cells for use as an immunotherapeutic strategy for immunocompromised patients. Cytotherapy, 2018, 20, 385-393.	0.3	15
90	How I treat T-cell chronic active Epstein-Barr virus disease. Blood, 2018, 131, 2899-2905.	0.6	72

#	Article	IF	Citations
91	Introduction to a review series on emerging immunotherapies for hematologic diseases. Blood, 2018, 131, 2617-2620.	0.6	7
92	A single exercise bout augments adenovirus-specific T-cell mobilization and function. Physiology and Behavior, 2018, 194, 56-65.	1.0	21
93	Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the Î²2-adrenergic receptor. Brain, Behavior, and Immunity, 2018, 68, 66-75.	2.0	36
94	Virus-Specific T Cells: Broadening Applicability. Biology of Blood and Marrow Transplantation, 2018, 24, 13-18.	2.0	37
95	Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!. Blood Reviews, 2018, 32, 203-224.	2.8	21
96	Introduction to a review series on therapeutic antibodies. Blood, 2018, 131, 1-1.	0.6	47
97	Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 592-603.	1.8	9
98	Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 1128-1139.	0.8	137
99	Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. Journal of Clinical Investigation, 2018, 128, 876-889.	3.9	157
100	HIV-Specific, ExÂVivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. Molecular Therapy, 2018, 26, 2496-2506.	3.7	32
101	EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood, 2018, 132, 2351-2361.	0.6	49
102	Î²2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain, Behavior, and Immunity, 2018, 74, 143-153.	2.0	80
103	Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency. Biology of Blood and Marrow Transplantation, 2018, 24, 1944-1946.	2.0	6
104	Malignant Lymphomas in Childhood. , 2018, , 1330-1342.e5.		2
105	Adoptive T Cell Therapy for Epsteinâ€“Barr Virus Complications in Patients With Primary Immunodeficiency Disorders. Frontiers in Immunology, 2018, 9, 556.	2.2	27
106	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood, 2018, 132, 1438-1451.	0.6	78
107	A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae. Molecular Therapy - Methods and Clinical Development, 2018, 9, 305-312.	1.8	24
108	Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1. Blood, 2018, 132, 1625-1625.	0.6	2

#	Article	IF	Citations
109	Ex vivo expanded multi-antigen specific lymphocytes for the treatment of solid tumors.. Journal of Clinical Oncology, 2018, 36, 3042-3042.	0.8	3
110	Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 8006-8006.	0.8	8
111	Specific Adoptive T-Cell Therapy for Viral and Fungal Infections. , 2018, , 395-411.		1
112	Cord blood natural killer cells expressing a dominant negative TGF-Î² receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy, 2017, 19, 408-418.	0.3	97
113	Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders. Current Allergy and Asthma Reports, 2017, 17, 3.	2.4	10
114	HIV Receives a â€œOne Two Knockout Punchâ€• Molecular Therapy, 2017, 25, 566-567.	3.7	0
115	Mobilizing Immune Cells With Exercise for Cancer Immunotherapy. Exercise and Sport Sciences Reviews, 2017, 45, 163-172.	1.6	37
116	Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood. Molecular Therapy - Methods and Clinical Development, 2017, 5, 13-21.	1.8	38
117	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. British Journal of Haematology, 2017, 177, 457-466.	1.2	158
118	Outcomes of adults and children with primary mediastinal Bâ€cell lymphoma treated with doseâ€adjusted <scp>EPOCH</scp>â€R. British Journal of Haematology, 2017, 179, 739-747.	1.2	101
119	Complete remissions post infusion of multiple tumor antigen specific T cells for the treatment of high risk leukemia and lymphoma patients after HCT. Cytotherapy, 2017, 19, e3.	0.3	5
120	Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine, 2017, 23, 52-58.	2.7	29
121	Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 771-781.	1.7	122
122	EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods in Molecular Biology, 2017, 1532, 255-265.	0.4	16
123	Developing T-cell therapies for lymphoma without receptor engineering. Hematology American Society of Hematology Education Program, 2017, 2017, 622-631.	0.9	2
124	Developing T-cell therapies for lymphoma without receptor engineering. Blood Advances, 2017, 1, 2579-2590.	2.5	7
125	Clinical and immunological responses after CD30-specific chimeric antigen receptorâ€“redirected lymphocytes. Journal of Clinical Investigation, 2017, 127, 3462-3471.	3.9	301
126	Virus-Specific T Cells for the Immunocompromised Patient. Frontiers in Immunology, 2017, 8, 1272.	2.2	72

#	Article	IF	Citations
127	Virus-Specific T Cells for Hematopoietic Stem Cell Transplantation. Current Stem Cell Reports, 2017, 3, 290-300.	0.7	0
128	Engineering cord blood to improve engraftment after cord blood transplant. Stem Cell Investigation, 2017, 4, 41-41.	1.3	20
129	Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Current Drug Targets, 2017, 18, 271-280.	1.0	7
130	PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy, 2016, 18, 995-1001.	0.3	9
131	A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy. Scientific Reports, 2016, 6, 25852.	1.6	22
132	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica, 2016, 101, 531-540.	1.7	75
133	Introduction to a review series on advances in cell-based immune therapeutics in hematology. Blood, 2016, 127, 3293-3293.	0.6	2
134	T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood, 2016, 127, 3331-3340.	0.6	177
135	Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. Cytotherapy, 2016, 18, 1515-1524.	0.3	33
136	Cellular therapy for sickle cell disease. Cytotherapy, 2016, 18, 1360-1369.	0.3	13
137	Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy. Nanomedicine, 2016, 11, 1759-1767.	1.7	56
138	Rare Pediatric Non-Hodgkin Lymphomas: A Report From Children's Oncology Group Study ANHL 04B1. Pediatric Blood and Cancer, 2016, 63, 794-800.	0.8	43
139	Enhancing The Generation Of Adenovirus-Specific T Cells With Exercise For Immunotherapy. Medicine and Science in Sports and Exercise, 2016, 48, 86-87.	0.2	1
140	T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy, 2016, 18, 931-942.	0.3	36
141	Gene Modification of Human Natural Killer Cells Using a Retroviral Vector. Methods in Molecular Biology, 2016, 1441, 203-213.	0.4	11
142	Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-NaÃ¯ve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 536-541.	2.0	34
143	Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. Journal of Allergy and Clinical Immunology, 2016, 137, 1498-1505.e1.	1.5	117
144	Human cytomegalovirus infection and the immune response to exercise. Exercise Immunology Review, 2016, 22, 8-27.	0.4	36

#	Article	IF	Citations
145	Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma Post Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, S148.	2.0	1
146	Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood, 2015, 125, 2885-2892.	0.6	118
147	T-Cell Immunotherapy for Cancer. , 2015, , 389-410.		0
148	Directed T-cell therapies for leukemia and lymphoma after hematopoietic stem cell transplant: beyond chimeric antigen receptors. International Journal of Hematologic Oncology, 2015, 4, 99-111.	0.7	0
149	Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Therapeutic Advances in Hematology, 2015, 6, 295-307.	1.1	16
150	Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood. Cytotherapy, 2015, 17, 749-755.	0.3	18
151	Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. Journal of Infectious Diseases, 2015, 212, 258-263.	1.9	86
152	Matched Related and Unrelated Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency. Biology of Blood and Marrow Transplantation, 2015, 21, 1037-1045.	2.0	45
153	Administration of LMP-specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive lymphoma post allogeneic stem cell transplant. Cytotherapy, 2015, 17, S18.	0.3	2
154	A single bout of dynamic exercise by healthy adults enhances the generation of monocyte-derived-dendritic cells. Cellular Immunology, 2015, 295, 52-59.	1.4	23
155	CMV-specific T cells generated from naÃ¯ve T cells recognize atypical epitopes and may be protective in vivo. Science Translational Medicine, 2015, 7, 285ra63.	5.8	93
156	Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy. Molecular Therapy, 2015, 23, 387-395.	3.7	46
157	General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1284-1290.	2.0	51
158	Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: Impact of latent cytomegalovirus infection and catecholamine sensitivity. Brain, Behavior, and Immunity, 2015, 49, 59-65.	2.0	38
159	T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica, 2015, 100, 709-719.	1.7	30
160	Quantitative activation suppression assay to evaluate human bone marrowâ€“derived mesenchymal stromal cell potency. Cytotherapy, 2015, 17, 1675-1686.	0.3	31
161	Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients. Cytotherapy, 2015, 17, 1667-1674.	0.3	15
162	Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells. Molecular Therapy, 2015, 23, 179-183.	3.7	28

#	Article	IF	Citations
163	Pediatric Lymphomas and Histiocytic Disorders of Childhood. Pediatric Clinics of North America, 2015, 62, 139-165.	0.9	77
164	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. Biology of Blood and Marrow Transplantation, 2015, 21, 402-411.	2.0	8
165	Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens. Blood, 2015, 126, 186-186.	0.6	13
166	The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation. Annals of Translational Medicine, 2015, 3, 62.	0.7	13
167	Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years. Blood, 2015, 126, 1926-1926.	0.6	0
168	A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults. Exercise Immunology Review, 2015, 21, 144-53.	0.4	27
169	Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation. ImmunoTargets and Therapy, 2014, 3, 97.	2.7	0
170	Controlling Cytomegalovirus: Helping the Immune System Take the Lead. Viruses, 2014, 6, 2242-2258.	1.5	66
171	A Change in the Editorial Office: Farewell from Catherine M. Bollard. Pediatric Hematology and Oncology, 2014, 31, 393-394.	0.3	0
172	Cytotoxic T lymphocytes for leukemia and lymphoma. Hematology American Society of Hematology Education Program, 2014, 2014, 565-569.	0.9	20
173	Opportunities and challenges of proteomics in pediatric patients: Circulating biomarkers after hematopoietic stem cell transplantation as a successful example. Proteomics - Clinical Applications, 2014, 8, 837-850.	0.8	4
174	Reply to S. Yuan et al. Journal of Clinical Oncology, 2014, 32, 2820-2821.	0.8	0
175	Complementation of Antigen-presenting Cells to Generate T Lymphocytes With Broad Target Specificity. Journal of Immunotherapy, 2014, 37, 193-203.	1.2	42
176	Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy, 2014, 16, 1153-1157.	0.3	10
177	Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy, 2014, 16, 84-89.	0.3	42
178	Third-party umbilical cord bloodâ€“derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy, 2014, 16, 90-100.	0.3	53
179	Immunotherapy: opportunities, risks and future perspectives. Cytotherapy, 2014, 16, S120-S129.	0.3	8
180	Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. Journal of Clinical Oncology, 2014, 32, 798-808.	0.8	433

#	Article	IF	Citations
181	Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity. Clinical Cancer Research, 2014, 20, 2215-2225.	3.2	176
182	Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Translational Medicine, 2014, 3, 1435-1443.	1.6	75
183	Pediatric Burkitt's Lymphoma and Diffuse B-Cell Lymphoma: Are Surveillance Scans Required?. Pediatric Hematology and Oncology, 2014, 31, 253-257.	0.3	25
184	Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain, Behavior, and Immunity, 2014, 39, 160-171.	2.0	121
185	The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy, 2014, 16, 149-159.	0.3	66
186	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e1-e5.	0.2	21
187	Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Molecular Therapy, 2014, 22, 1388-1395.	3.7	106
188	The effects of age and latent cytomegalovirus infection on the redeployment of CD8+ T cell subsets in response to acute exercise in humans. Brain, Behavior, and Immunity, 2014, 39, 142-151.	2.0	53
189	FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT. Blood, 2014, 124, 1147-1147.	0.6	0
190	A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency. Blood, 2014, 124, 316-316.	0.6	0
191	Highlights of the Third International Conference on Immunotherapy in Pediatric Oncology. Pediatric Hematology and Oncology, 2013, 30, 349-366.	0.3	3
192	Children's Oncology Group's 2013 blueprint for research: Nonâ€Hodgkin lymphoma. Pediatric Blood and Cancer, 2013, 60, 979-984.	0.8	35
193	Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemiaâ€"Implications for Immunotherapy. Clinical Cancer Research, 2013, 19, 5079-5091.	3.2	81
194	Cord Blood Graft Engineering. Biology of Blood and Marrow Transplantation, 2013, 19, S74-S78.	2.0	16
195	The 2013 Educational Supplement on Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, S1.	2.0	1
196	Enhancing Immune Reconstitution: From Bench to Bedside. Biology of Blood and Marrow Transplantation, 2013, 19, S79-S83.	2.0	12
197	Improving T-Cell Therapy for Epstein-Barr Virus Lymphoproliferative Disorders. Journal of Clinical Oncology, 2013, 31, 5-7.	0.8	42
198	T-cell therapies for HIV. Immunotherapy, 2013, 5, 407-414.	1.0	43

#	Article	IF	Citations
199	Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients. Pediatric Hematology and Oncology, 2013, 30, 520-531.	0.3	50
200	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood, 2013, 121, 5113-5123.	0.6	507
201	Scouting out the neighborhood in AIDS-related lymphoma. Blood, 2013, 122, 306-307.	0.6	11
202	Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood, 2013, 122, 2965-2973.	0.6	470
203	Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. PLoS ONE, 2013, 8, e76781.	1.1	155
204	Multi-Virus-Specific T-Cell Therapy For Patients After Hematopoietic Stem Cell and Cord Blood Transplantation. Blood, 2013, 122, 140-140.	0.6	16
205	Whole genome sequencing of sporadic Burkitt lymphoma in HIV-infected and uninfected patients.. Journal of Clinical Oncology, 2013, 31, 8577-8577.	0.8	0
206	T-cell therapy for cancer. Immunotherapy, 2012, 4, 347-350.	1.0	3
207	T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nature Reviews Clinical Oncology, 2012, 9, 510-519.	12.5	230
208	Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma. Journal of Immunotherapy, 2012, 35, 159-168.	1.2	59
209	Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture. New England Journal of Medicine, 2012, 367, 2305-2315.	13.9	430
210	Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus. Journal of Visualized Experiments, 2012, , e3627.	0.2	20
211	Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epsteinâ€“Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy, 2012, 14, 7-11.	0.3	39
212	Aggressive peripheral CD70â€positive tâ€cell lymphoma associated with severe chronic active EBV infection. Pediatric Blood and Cancer, 2012, 59, 758-761.	0.8	5
213	ExÂvivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2RÎ³null mice. Experimental Hematology, 2012, 40, 445-456.	0.2	84
214	Reply to Sackstein. Experimental Hematology, 2012, 40, 519-520.	0.2	1
215	Improving Immune Reconstitution After Cord Blood Transplantation Using Ex Vivo Expanded Virus-Specific T Cells: A Phase I Clinical Study. Blood, 2012, 120, 224-224.	0.6	2
216	Multicenter Study of â€œoff-the-Shelfâ€•Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2012, 120, 457-457.	0.6	2

#	Article	IF	Citations
217	Expansion of T cells targeting multiple antigens of cytomegalovirus, Epsteinâ€“Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy, 2011, 13, 976-986.	0.3	50
218	Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epsteinâ€“Barr virus-associated lymphoma. Cytotherapy, 2011, 13, 518-522.	0.3	25
219	Novel Cord Blood Transplant Therapies. Biology of Blood and Marrow Transplantation, 2011, 17, S39-S45.	2.0	13
220	Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4. Clinical Cancer Research, 2011, 17, 7058-7066.	3.2	72
221	Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood, 2011, 117, 5835-5849.	0.6	241
222	Sobering realities of surviving Hodgkin Lymphoma. Blood, 2011, 117, 1772-1773.	0.6	17
223	Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. Molecular Therapy, 2011, 19, 2258-2268.	3.7	80
224	Hodgkin Disease and the Role of the Immune System. Pediatric Hematology and Oncology, 2011, 28, 176-186.	0.3	34
225	T-Cell Therapies for Epstein-Barr Virusâ€“Associated Lymphomas. Pediatric Hematology and Oncology, 2011, 28, 627-639.	0.3	10
226	CD28 costimulation improves expansion and persistence of chimeric antigen receptorâ€“modified T cells in lymphoma patients. Journal of Clinical Investigation, 2011, 121, 1822-1826.	3.9	876
227	Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes. Blood, 2011, 118, 155-155.	0.6	4
228	Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1794-1794.	0.6	2
229	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. Blood, 2011, 118, 246-246.	0.6	1
230	Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,. Blood, 2011, 118, 4043-4043.	0.6	0
231	Generation of Multi-Antigen Specific T Cells for Adoptive Immunotherapy of Myeloid Leukemia and Identification of MHC Class I and II-Restricted Peptides for WT1, Proteinase 3 and Human Neutrophil Elastase. Blood, 2011, 118, 2985-2985.	0.6	4
232	Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2855-2855.	0.6	0
233	Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma. Journal of Immunotherapy, 2010, 33, 983-990.	1.2	201
234	Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion. Journal of Immunotherapy, 2010, 33, 684-696.	1.2	58

#	Article	IF	Citations
235	Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 2010, 115, 925-935.	0.6	721
236	Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood, 2010, 116, 4700-4702.	0.6	176
237	A novel latent membrane 2 transcript expressed in Epstein-Barr virusâ€“positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood, 2010, 116, 3695-3704.	0.6	63
238	Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy, 2010, 12, 713-720.	0.3	27
239	Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 870-880.	0.6	44
240	Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy, 2010, 12, 743-749.	0.3	75
241	Isolating cytomegalovirus-specific T cells for adoptive transfer: are we there yet?. Cytotherapy, 2010, 12, 857-858.	0.3	0
242	Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood, 2010, 115, 2695-2703.	0.6	105
243	Allogeneic Virus-Specific T Cells with HLA Alloreactivity Do Not Produce Graft-Versus-Host Disease In Human Subjects. Blood, 2010, 116, 1252-1252.	0.6	1
244	The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction. Blood, 2010, 116, 2850-2850.	0.6	3
245	Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils. Blood, 2010, 116, 362-362.	0.6	14
246	Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2010, 116, 829-829.	0.6	98
247	Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. Blood, 2010, 116, 2453-2453.	0.6	0
248	Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. Blood, 2010, 116, 2100-2100.	0.6	0
249	Anti-Viral Cytotoxic T-Lymphocyte Therapy. Blood, 2010, 116, SCI-50-SCI-50.	0.6	0
250	The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies. Blood, 2010, 116, 3949-3949.	0.6	0
251	Noninvasive Bioluminescent Imaging Demonstrates Long-Term Multilineage Engraftment of Ex Vivo-Expanded CD34-Selected Umbilical Cord Blood Cells. Stem Cells, 2009, 27, 1932-1940.	1.4	16
252	De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination. Vaccine, 2009, 27, 1479-1484.	1.7	19

#	Article	IF	Citations
253	Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood, 2009, 113, 2442-2450.	0.6	107
254	Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood, 2009, 114, 1958-1967.	0.6	235
255	Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood, 2009, 114, 4283-4292.	0.6	311
256	The Histone Deacetylase (HDAC) Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction.. Blood, 2009, 114, 1562-1562.	0.6	5
257	Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2RÎ³null (NSG) Mice as a Model.. Blood, 2009, 114, 2370-2370.	0.6	1
258	Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy.. Blood, 2009, 114, 504-504.	0.6	0
259	Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. Blood, 2009, 114, 3212-3212.	0.6	0
260	Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant.. Blood, 2009, 114, 4089-4089.	0.6	7
261	Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia.. Blood, 2009, 114, 3029-3029.	0.6	0
262	Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Practice and Research in Clinical Haematology, 2008, 21, 405-420.	0.7	24
263	Comparable Outcome of Alternative Donor and Matched Sibling Donor Hematopoietic Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia in First or Second Remission Using Alemtuzumab in a Myeloablative Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2008, 14, 1245-1252.	2.0	45
264	Successful Treatment of Stem Cell Graft Failure in Pediatric Patients Using a Submyeloablative Regimen of Campath-1H and Fludarabine. Biology of Blood and Marrow Transplantation, 2008, 14, 1298-1304.	2.0	21
265	Current understanding of the role of Epsteinâ€“Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leukemia and Lymphoma, 2008, 49, 27-34.	0.6	124
266	Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy. Journal of Virology, 2008, 82, 546-554.	1.5	129
267	Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-Î² Receptor. Journal of Immunotherapy, 2008, 31, 500-505.	1.2	197
268	Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. Blood, 2008, 112, 230-230.	0.6	0
269	The â€œSide-Populationâ€•of Human Lymphoma Cells Have Increased Chemo-Resistance, Stem-Cell Like Properties and Are Potential Targets for Immunotherapy. Blood, 2008, 112, 2620-2620.	0.6	0
270	Selective Loss of a Putative Precursor Population of B-Chronic Lymphocytic Leukemia Cells Following Immunization with hCD40L/IL-2 Expressing Autologous Tumor Cells. Blood, 2008, 112, 3172-3172.	0.6	0

#	Article	IF	Citations
271	Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia. Blood, 2008, 112, 2905-2905.	0.6	0
272	Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy. Blood, 2008, 112, 3505-3505.	0.6	0
273	Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood, 2007, 110, 2838-2845.	0.6	266
274	Autologous Designer Antigen-presenting Cells by Gene Modification of T Lymphocyte Blasts With IL-7 and IL-12. Journal of Immunotherapy, 2007, 30, 506-516.	1.2	23
275	Adoptive immunotherapy for herpesviruses. , 2007, , 1318-1331.		2
276	Generation of Influenza HA-Specific Lymphocytes from Autologous Umbilical Cord Blood-Derived Dendritic Cells.. Blood, 2007, 110, 3875-3875.	0.6	0
277	Deficient Th-1 Responses from TNFÎ±-Matured Dendritic Cells.. Blood, 2007, 110, 3839-3839.	0.6	0
278	In vivoexpansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2006, 47, 837-842.	0.6	27
279	Administration of Latent Membrane Protein 2â€“Specific Cytotoxic T Lymphocytes to Patients with Relapsed Epstein-Barr Virusâ€“Positive Lymphoma. Clinical Lymphoma and Myeloma, 2006, 6, 342-347.	1.4	19
280	Adenoviral Infections in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 243-251.	2.0	50
281	Assessing the Safety of Cytotoxic T Lymphocytes Transduced With a Dominant Negative Transforming Growth Factor-Î² Receptor. Journal of Immunotherapy, 2006, 29, 250-260.	1.2	44
282	Adoptive Tâ€cell transfer in cancer immunotherapy. Immunology and Cell Biology, 2006, 84, 281-289.	1.0	38
283	Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine, 2006, 12, 1160-1166.	15.2	536
284	Presentation of Epstein Barr Virus (EBV) Epitopes by Activated Human Î³Î´ T Cells Induces Peptide-Specific Cytolytic CD8+ T Cell Expansion.. Blood, 2006, 108, 1738-1738.	0.6	5
285	Treatment of nasopharyngeal carcinoma with Epstein-Barr virusâ€“specific T lymphocytes. Blood, 2005, 105, 1898-1904.	0.6	344
286	Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma. Journal of Immunology, 2005, 175, 4137-4147.	0.4	72
287	Hodgkin's disease: are you the type?. Lancet, The, 2005, 365, 2162-2163.	6.3	1
288	Outcome of Alternative Donor Transplantation for Severe Aplastic Anemia Can Be Comparable to Outcome with Matched Related Donors.. Blood, 2005, 106, 2052-2052.	0.6	0

#	Article	IF	Citations
289	Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders.. Blood, 2005, 106, 2746-2746.	0.6	0
290	The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma.. Blood, 2005, 106, 773-773.	0.6	0
291	Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease. Journal of Experimental Medicine, 2004, 200, 1623-1633.	4.2	371
292	A strategy for treatment of Epsteinâ€“Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Therapy, 2004, 11, 81-91.	2.2	74
293	Adoptive immunotherapy for posttransplantation viral infections. Biology of Blood and Marrow Transplantation, 2004, 10, 143-155.	2.0	76
294	The Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease. Journal of Immunotherapy, 2004, 27, 317-327.	1.2	96
295	LMP2-Cytotoxic T Lymphocyte Therapy for Relapsed EBV Positive Lymphoma.. Blood, 2004, 104, 3276-3276.	0.6	2
296	Adoptive T-Cell Therapy for EBV-Associated Post-Transplant Lymphoproliferative Disease. Acta Haematologica, 2003, 110, 139-148.	0.7	43
297	Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood, 2003, 102, 2292-2299.	0.6	139
298	Epstein-Barr virusâ€“specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood, 2002, 99, 2009-2016.	0.6	185
299	Adapting a transforming growth factor Î²â€“related tumor protection strategy to enhance antitumor immunity. Blood, 2002, 99, 3179-3187.	0.6	310
300	Gene therapy for paediatric leukaemia. Expert Opinion on Biological Therapy, 2001, 1, 663-674.	1.4	5
301	Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. International Journal of Cancer, 2001, 94, 228-236.	2.3	143
302	Gene-Marking studies of hematopoietic cells. International Journal of Hematology, 2001, 73, 14-22.	0.7	11
303	Adoptive Immunotherapy. , 0, , 920-935.		0
304	Immune therapy with cytotoxic T-lymphocytes for treatment of infections. , 0, , 611-625.		0
305	BCL-2 Antagonism Sensitizes CTL-Resistant HIV Reservoirs to Elimination Ex Vivo. SSRN Electronic Journal, 0, , .	0.4	2
306	Assessment of ST2 for Risk of Death Following Graft-versus-Host Disease in the Pediatric and Adult Age Groups. SSRN Electronic Journal, 0, , .	0.4	1

#	Article	IF	Citations
307	A Participant-Derived Xenograft Model of HIV Enables Long-Term Evaluation of Autologous Immunotherapies. SSRN Electronic Journal, 0, , .	0.4	1